{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:24:30Z","timestamp":1761513870180},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>While previous studies have researched in association analyses between TNF\u03b1 promoter polymorphisms and responses to TNF blockers in spondyloarthritis patients, their results were conflicting. Therefore, we aimed to determine whether TNF\u03b1 promoter polymorphisms could predict response to TNF blockers and find the source of heterogeneity. Data were extracted and analyzed from published articles and combined with our unpublished data. We found that the greatest potential sources of heterogeneity in the results were gender ratio, disease type, continents and TNF blockers. Then Stratification analysis showed that the TNF\u03b1 \u2212308 G allele and the \u2212238 G allele predicted a good response to TNF blockers (OR\u2009=\u20092.64 [1.48\u20134.73]; 2.52 [1.46\u20134.37]). However, G alleles of TNF\u03b1 \u2212308 and \u2212238 could predict the response to etanercept (OR\u2009=\u20094.02 [2.24\u20137.23]; 5.17 [2.29\u201311.67]) much more powerfully than the response to infiliximab\/adalimumab (OR\u2009=\u20091.68 [1.02\u20132.78]; 1.28 [0.57\u20132.86]). TNF\u03b1 \u2212857 could not predict the response in either subgroup. Cumulative meta-analysis performed in ankylosing spondylitis patients presented the odds ratio decreased with stricter response criteria. In conclusion, TNF\u03b1 \u2212308 A\/G and \u2212238 A\/G are more powerful to predict the response to Etanercept and it is dependent on the criteria of response.<\/jats:p>","DOI":"10.1038\/srep32202","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T16:44:39Z","timestamp":1472661879000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["TNF-\u03b1 Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab\/Adalimumab in Spondyloarthritis"],"prefix":"10.1038","volume":"6","author":[{"given":"Jing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongyi","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiping","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongbao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiucun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"key":"BFsrep32202_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/s0140-6736(07)60635-7","volume":"369","author":"J Braun","year":"2007","unstructured":"Braun, J. & Sieper, J. Ankylosing spondylitis. The Lancet 369, 1379\u20131390, doi: 10.1016\/s0140-6736(07)60635-7 (2007).","journal-title":"The Lancet"},{"key":"BFsrep32202_CR2","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.berh.2014.10.007","volume":"28","author":"N Garg","year":"2014","unstructured":"Garg, N., van den Bosch, F. & Deodhar, A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol 28, 663\u2013672, doi: 10.1016\/j.berh.2014.10.007 (2014).","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"BFsrep32202_CR3","doi-asserted-by":"publisher","first-page":"4858","DOI":"10.1074\/jbc.275.7.4858","volume":"275","author":"Y Azuma","year":"2000","unstructured":"Azuma, Y., Kaji, K., Katogi, R., Takeshita, S. & Kudo, A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 275, 4858\u20134864 (2000).","journal-title":"J Biol Chem"},{"key":"BFsrep32202_CR4","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.bbrc.2004.12.180","volume":"328","author":"BB Scott","year":"2005","unstructured":"Scott, B. B. et al. TNF-alpha modulates angiopoietin-1 expression in rheumatoid synovial fibroblasts via the NF-kappa B signalling pathway. Biochem Biophys Res Commun 328, 409\u2013414, doi: 10.1016\/j.bbrc.2004.12.180 (2005).","journal-title":"Biochem Biophys Res Commun"},{"key":"BFsrep32202_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1096\/fasebj.11.6.9194526","volume":"11","author":"JR Jackson","year":"1997","unstructured":"Jackson, J. R., Seed, M. P., Kircher, C. H., Willoughby, D. A. & Winkler, J. D. The codependence of angiogenesis and chronic inflammation. Faseb j 11, 457\u2013465 (1997).","journal-title":"Faseb j"},{"key":"BFsrep32202_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1080\/03009740510026599","volume":"34","author":"J Braun","year":"2005","unstructured":"Braun, J., Baraliakos, X., Brandt, J. & Sieper, J. Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides. Scand J Rheumatol 34, 178\u2013190 (2005).","journal-title":"Scand J Rheumatol"},{"key":"BFsrep32202_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/nrrheum.2012.40","volume":"8","author":"J Sieper","year":"2012","unstructured":"Sieper, J. Developments in therapies for spondyloarthritis. Nat Rev Rheumatol 8, 280\u2013287, doi: 10.1038\/nrrheum.2012.40 (2012).","journal-title":"Nat Rev Rheumatol"},{"key":"BFsrep32202_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.2217\/14622416.8.7.761","volume":"8","author":"MJ Coenen","year":"2007","unstructured":"Coenen, M. J. et al. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. Pharmacogenomics 8, 761\u2013773, doi: 10.2217\/14622416.8.7.761 (2007).","journal-title":"Pharmacogenomics"},{"key":"BFsrep32202_CR9","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1186\/ar2001","volume":"8","author":"B Vander Cruyssen","year":"2006","unstructured":"Vander Cruyssen, B. et al. Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity. Arthritis Res Ther 8, R112, doi: 10.1186\/ar2001 (2006).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep32202_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","volume":"126","author":"J Lin","year":"2008","unstructured":"Lin, J. et al. TNFalpha blockade in human diseases: an overview of efficacy and safety. Clin Immunol 126, 13\u201330, doi: 10.1016\/j.clim.2007.08.012 (2008).","journal-title":"Clin Immunol"},{"key":"BFsrep32202_CR11","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease, P. J. et al. Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arthritis Rheum 50, 2264\u20132272, doi: 10.1002\/art.20335 (2004).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32202_CR12","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1080\/713786515","volume":"37","author":"E Louis","year":"2002","unstructured":"Louis, E. et al. Inflammatory Bowel Disease A Positive Response to Infliximab in Crohn Disease: Association with a Higher Systemic Inflammation Before Treatment But Not With \u2212308 TNF Gene Polymorphism. Scandinavian Journal of Gastroenterology 37, 818\u2013824, doi: 10.1080\/713786515 (2002).","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"BFsrep32202_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","volume":"46","author":"M Seitz","year":"2007","unstructured":"Seitz, M., Wirthmuller, U., Moller, B. & Villiger, P. M. The \u2212308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 46, 93\u201396, doi: 10.1093\/rheumatology\/kel175 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep32202_CR14","first-page":"35","volume":"24","author":"K Papamichael","year":"2011","unstructured":"Papamichael, K. et al. Association of and gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn\u2019s disease patients. Ann Gastroenterol 24, 35\u201340 (2011).","journal-title":"Ann Gastroenterol"},{"key":"BFsrep32202_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2165\/11594660-000000000-00000","volume":"16","author":"Y Vasilopoulos","year":"2012","unstructured":"Vasilopoulos, Y. et al. Pharmacogenetic analysis of TNF, TNFRSF1A and TNFRSF1B gene polymorphisms and prediction of response to anti-TNF therapy in psoriasis patients in the Greek population. Mol Diagn Ther 16, 29\u201334, doi: 10.2165\/11594660-000000000-00000 (2012).","journal-title":"Mol Diagn Ther"},{"key":"BFsrep32202_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2217\/pgs.12.133","volume":"13","author":"Q Tong","year":"2012","unstructured":"Tong, Q. et al. TNF-alpha \u2212857 and \u22121031 polymorphisms predict good therapeutic response to TNF-alpha blockers in Chinese Han patients with ankylosing spondylitis. Pharmacogenomics 13, 1459\u20131467, doi: 10.2217\/pgs.12.133 (2012).","journal-title":"Pharmacogenomics"},{"key":"BFsrep32202_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/iji.12059","volume":"41","author":"R Lopez-Hernandez","year":"2014","unstructured":"Lopez-Hernandez, R. et al. Genetic polymorphisms of tumour necrosis factor alpha (TNF-alpha) promoter gene and response to TNF-alpha inhibitors in Spanish patients with inflammatory bowel disease. Int J Immunogenet 41, 63\u201368, doi: 10.1111\/iji.12059 (2014).","journal-title":"Int J Immunogenet"},{"key":"BFsrep32202_CR18","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/bjd.12425","volume":"169","author":"E Gallo","year":"2013","unstructured":"Gallo, E. et al. The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: a case-control study. Br J Dermatol 169, 819\u2013829, doi: 10.1111\/bjd.12425 (2013).","journal-title":"Br J Dermatol"},{"key":"BFsrep32202_CR19","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1038\/jid.2014.123","volume":"134","author":"G Murdaca","year":"2014","unstructured":"Murdaca, G. et al. TNF-alpha gene polymorphisms: association with disease susceptibility and response to anti-TNF-alpha treatment in psoriatic arthritis. J Invest Dermatol 134, 2503\u20132509, doi: 10.1038\/jid.2014.123 (2014).","journal-title":"J Invest Dermatol"},{"key":"BFsrep32202_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1111\/jdv.13024","volume":"29","author":"C De Simone","year":"2015","unstructured":"De Simone, C. et al. TNF-alpha gene polymorphisms can help to predict response to etanercept in psoriatic patients. J Eur Acad Dermatol Venereol 29, 1786\u20131790, doi: 10.1111\/jdv.13024 (2015).","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"BFsrep32202_CR21","first-page":"157","volume":"42","author":"JW Chen","year":"2011","unstructured":"Chen, J. W., Peng, W. F., Mao, N. & Xie, X. The association study of polymorphism in the promoter region \u2212308 tumor necrosis factor-\u03b1 gene with etanercept treatment in ankylosing spondylitis. J New Med (Chinese) 42, 157\u2013159 (2011).","journal-title":"J New Med (Chinese)"},{"key":"BFsrep32202_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/jlb.66.4.562","volume":"66","author":"LJ Abraham","year":"1999","unstructured":"Abraham, L. J. & Kroeger, K. M. Impact of the \u2212308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 66, 562\u2013566 (1999).","journal-title":"J Leukoc Biol"},{"key":"BFsrep32202_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1046\/j.1365-2125.2001.00321.x","volume":"51","author":"HE Seymour","year":"2001","unstructured":"Seymour, H. E., Worsley, A., Smith, J. M. & Thomas, S. H. Anti-TNF agents for rheumatoid arthritis. Br J Clin Pharmacol 51, 201\u2013208 (2001).","journal-title":"Br J Clin Pharmacol"},{"key":"BFsrep32202_CR24","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1093\/rheumatology\/kem261","volume":"46","author":"M Svenson","year":"2007","unstructured":"Svenson, M., Geborek, P., Saxne, T. & Bendtzen, K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. Rheumatology (Oxford) 46, 1828\u20131834, doi: 10.1093\/rheumatology\/kem261 (2007).","journal-title":"Rheumatology (Oxford)"},{"key":"BFsrep32202_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/ard.2008.089979","volume":"68","author":"MK de Vries","year":"2009","unstructured":"de Vries, M. K. et al. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68, 531\u2013535, doi: 10.1136\/ard.2008.089979 (2009).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32202_CR26","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.jaad.2006.07.019","volume":"56","author":"JE Graves","year":"2007","unstructured":"Graves, J. E., Nunley, K. & Heffernan, M. P. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab and alefacept (part 2 of 2). J Am Acad Dermatol 56, e55\u201379, doi: 10.1016\/j.jaad.2006.07.019 (2007).","journal-title":"J Am Acad Dermatol"},{"key":"BFsrep32202_CR27","doi-asserted-by":"publisher","first-page":"604872","DOI":"10.1155\/2015\/604872","volume":"2015","author":"I Arstikyte","year":"2015","unstructured":"Arstikyte, I., Kapleryte, G., Butrimiene, I. & Venalis, A. Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF alpha Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. Biomed Res Int 2015, 604872, doi: 10.1155\/2015\/604872 (2015).","journal-title":"Biomed Res Int"},{"key":"BFsrep32202_CR28","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde, D. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11, R127, doi: 10.1186\/ar2794 (2009).","journal-title":"Arthritis Res Ther"},{"key":"BFsrep32202_CR29","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58, 1324\u20131331, doi: 10.1002\/art.23471 (2008).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32202_CR30","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde, D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58, 3063\u20133070, doi: 10.1002\/art.23901 (2008).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32202_CR31","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1136\/ard.2005.045658","volume":"65","author":"A Kavanaugh","year":"2006","unstructured":"Kavanaugh, A. et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 65, 1038\u20131043, doi: 10.1136\/ard.2005.045658 (2006).","journal-title":"Ann Rheum Dis"},{"key":"BFsrep32202_CR32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/art.21655","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde, D. et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 54, 1063\u20131074, doi: 10.1002\/art.21655 (2006).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32202_CR33","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"EC Keystone","year":"2004","unstructured":"Keystone, E. C. et al. Radiographic, clinical and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50, 1400\u20131411, doi: 10.1002\/art.20217 (2004).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32202_CR34","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/art.22590","volume":"56","author":"K Reich","year":"2007","unstructured":"Reich, K. et al. TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*\u2212857 independent of the PSORS1 risk allele. Arthritis Rheum 56, 2056\u20132064, doi: 10.1002\/art.22590 (2007).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32202_CR35","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2217\/pgs.13.146","volume":"14","author":"Q Tong","year":"2013","unstructured":"Tong, Q. et al. Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis. Pharmacogenomics 14, 1691\u20131700, doi: 10.2217\/pgs.13.146 (2013).","journal-title":"Pharmacogenomics"},{"key":"BFsrep32202_CR36","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.2217\/pgs.15.90","volume":"16","author":"GG Song","year":"2015","unstructured":"Song, G. G. et al. Association between TNF-alpha (\u2212308 A\/G, \u2212238 A\/G, \u2212857 C\/T) polymorphisms and responsiveness to TNF-alpha blockers in spondyloarthropathy, psoriasis and Crohn\u2019s disease: a meta-analysis. Pharmacogenomics 16, 1427\u20131437, doi: 10.2217\/pgs.15.90 (2015).","journal-title":"Pharmacogenomics"},{"key":"BFsrep32202_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/tpj.2015.49","volume":"16","author":"M Fabris","year":"2016","unstructured":"Fabris, M. et al. The \u2212308 TNFalpha and the \u2212174 IL-6 promoter polymorphisms associate with effective anti-TNFalpha treatment in seronegative spondyloarthritis. Pharmacogenomics J 16, 238\u2013242, doi: 10.1038\/tpj.2015.49 (2016).","journal-title":"Pharmacogenomics J"},{"key":"BFsrep32202_CR38","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::aid-art326>3.0.co;2-f","volume":"44","author":"JJ Anderson","year":"2001","unstructured":"Anderson, J. J., Baron, G., van der Heijde, D., Felson, D. T. & Dougados, M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44, 1876\u20131886, doi: 10.1002\/1529-0131(200108)44:8&lt;1876::aid-art326&gt;3.0.co;2-f (2001).","journal-title":"Arthritis Rheum"},{"key":"BFsrep32202_CR39","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett, S. et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21, 2286\u20132291 (1994).","journal-title":"J Rheumatol"},{"key":"BFsrep32202_CR40","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/sim.1187","volume":"21","author":"SG Thompson","year":"2002","unstructured":"Thompson, S. G. & Higgins, J. P. How should meta-regression analyses be undertaken and interpreted? Stat Med 21, 1559\u20131573, doi: 10.1002\/sim.1187 (2002).","journal-title":"Stat Med"},{"key":"BFsrep32202_CR41","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins, J. P. & Thompson, S. G. Quantifying heterogeneity in a meta-analysis. Stat Med 21, 1539\u20131558, doi: 10.1002\/sim.1186 (2002).","journal-title":"Stat Med"},{"key":"BFsrep32202_CR42","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel, N. & Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22, 719\u2013748 (1959).","journal-title":"J Natl Cancer Inst"},{"key":"BFsrep32202_CR43","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. Control Clin Trials 7, 177\u2013188 (1986).","journal-title":"Control Clin Trials"},{"key":"BFsrep32202_CR44","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","volume":"50","author":"CB Begg","year":"1994","unstructured":"Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088\u20131101 (1994).","journal-title":"Biometrics"},{"key":"BFsrep32202_CR45","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/S0895-4356(01)00377-8","volume":"54","author":"JA Sterne","year":"2001","unstructured":"Sterne, J. A. & Egger, M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 54, 1046\u20131055 (2001).","journal-title":"J Clin Epidemiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep32202","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep32202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T20:52:23Z","timestamp":1672865543000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep32202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,10,17]]}},"alternative-id":["BFsrep32202"],"URL":"https:\/\/doi.org\/10.1038\/srep32202","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]},"assertion":[{"value":"24 March 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"32202"}}